Abstract
Background: Women with polycystic ovarian syndrome (PCOS) often have insulin resistance and hyperinsulinaemia and may therefore be at an increased risk for gestational diabetes mellitus (GDM). Metformin is widely prescribed to pregnant women with PCOS in an attempt to reduce pregnancy complications. Metformin is not approved for this indication, and evidence for this practice is lacking
Aim: the objective of this study was to compare the pregnancy outcomes if metformin was continued till delivery in pregnant PCOS patientsto the outcomes if metformin was discontinued at 12 weeks.
Materials and methods: this single institution study included 81 women diagnosed with PCOS who conceived with metformin and randomised into two groups, group 1 who continues metformin till delivery and group 2 who discontinued metformin at 12 weeks. Obstetrical outcomes measured were GDM, Gestational hypertension, fetal growth restriction (FGR) and preterm delivery.
Results: Gestational hypertension was seen in 25% in group 1 and 33 % in group 2. 20% patients were found to have GDM in group 1 and 33% in group 2..Preterm labour rate in group 1 and group 2 were 25% and 33% respectively. Incidence of FGR was similar in both groups, 18%.
Conclusion: Metformin appeared to reduce the incidence of GDM, especially need for insulin initiation if taken throughout pregnancy. It also appeared to reduce the incidence of hypertensive complications and preterm labour in this study. Metformin appeared to have no correlation to fetal growth restriction as evidenced by this study.
Keywords: Polycystic ovarian syndrome, Metformin, Gestational hypertension, Gestational Diabetes Mellitus, Fetal Growth Restriction, Preterm Labour.
References
1. Dunaif A, Futterweit W, Segal KR, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165–74.
2. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest 1995;96:520–7.
3. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992;41:1257–66.
4. Sills ES, Perloe M, Palermo GD. Correction of hyperinsulinemia in oligoovulatory women with clomiphene-resistant polycystic ovary syndrome: a review of therapeutic rationale and reproductive outcomes. Eur J ObstetGynecolReprodBiol 2000;91:135–41.
5. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelezyk L. Metformin therapy dereaseshyperandrogenism and hyper-insulinemia in women with polycystic ovary syndrome. FertilSteril 2000;73:1149–54
6. De Leo V, la Marca A, Ditto A, Morgante G, Cianci A. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. FertilSteril 1999;72:282–5.
7. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J ClinEndocrinolMetab 2000;85:139– 46.
8. Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J EndocrinolMetab 1997;82:4075–79.
9. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J ClinEndocrinolMetab 1997;82:524–30.
10. Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformininduced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism 1999;48:511–519
11. David E. Poly cystic ovarian syndrome. N EnglJ Med 2005; 352: 1223–1236
12. Checa MA, Requena A, Salvador C et al. Insulin sensitizing agents. Use in pregnancy and as therapy in polycystic ovarian syndrome. Human Reprod Update 2005; 11: 375–390
13. Costello MF, Eden JA. A systematic review of reproductive system effects of metformin with polycytic ovarian syndrome. Fetilsteril 2003; 79: 1–13
14. Vanky E, Salvesen KA, Heimstad R, Fougner KJ, Romundstad P, Carlsen SM 2004 Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum Reprod 19:1734–1740
15. Vanky E, Stridsklev S, Heimstad R, Romundstad P, Sokogy K, Kleggetveit O, Hjelle S, von Brandis P, Eikeland T, Flo K, Berg KF, Bunford G, Lund A, Bjerke C, Almås I, Berg AH, Danielson A, Lahmami G, Carlsen SM 2010 Metformin vs placebo from first trimester to delivery in polycystic ovary syndrome: a randomized controlled multicenter study. J ClinEndocrinolMetab 95:E448–E45
16. Legro RS, Kunselaman AR, Dodson WC et al. Prevalance and risk factors for type 2 DM and impaired glucose tolerance in PCOS, a prospective controlled study in 254 affected women. J ClinEndocrinolMetab 1999; 84: 164–169.
17. Weerakiat S, Srisombut C, Bunaag P et al. Prevalance of type 2 DM and impaired glucose tolerance in Asian women with PCOS. Int J GynecolObstet 2001; 75: 177–184.
18. Haakova L, Cibala D, Rezabek K, Hill M. Pregnancy outcome in women with PCOS and control matched by age and weight. Hum Reprod 2003; 18: 1438–1441
19. Glueck CJ, Bornovali S, Pranikof FJ, Goldenberg NO, DharashirKar S, Wang P. Metformin and gestational diabetes. CurrDiab Rep 2003; 3: 310–312.
20. Hague WM, Davoren PM, Oliver J, Rowan J. Contraindication to use of Metformin. Metformin may be effective in gestational diabetes. Br Med J 2003; 326: 762.
21. Norman RJ, Kidson WJ, Coneo RC, Zaeharin MR. Metformin and intervention in polycystic ovarian syndrome. Endocrine Society of Australia, the Australian Diabetes Society and Australian Pediatric endocrine group. Am J Aust 2001; 174: 580–583.
22. Nawaz, F., Khalid, R., Naru, T., Rizvi, J. (2008). Does continuous use of metformin throughout pregnancy improve pregnancy outcomes in women with polycystic ovarian syndrome?.Journal of Obstetrics and Gynaecology Research, 34(5), 832-837
DOI: http://dx.doi.org/10.18535/jmscr/v4i5.21
